A Study in Participants With Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether baricitinib therapy alone is noninferior to
methotrexate (MTX) therapy alone in the treatment of moderate to severe active rheumatoid
arthritis (RA) in those who have had limited or no treatment with MTX and are naive to other
conventional or biologic disease-modifying antirheumatic drugs (DMARDs).